Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Benzocaine studies

This article was originally published in The Tan Sheet

Executive Summary

A retrospective analysis of the dose-response relationship between 10% and 20% strengths of benzocaine "does not adequately support the dose response" of drug, FDA says in Oct. 29 letter responding to CHPA data submission (1"The Tan Sheet" July 8, 2002, p. 15). Agency reiterates call for one efficacy study to evaluate both 10%, 20% benzocaine compared with placebo for toothache. In addition, FDA advises study labeling must include language that directs consumer to seek treatment if relief is not obtained after several doses. Finally, agency requests updated assessment of methemoglobinemia cases associated with benzocaine use...
Advertisement

Related Content

Benzocaine Dose-Response Seen Strongest In Severe Toothache Pain – CHPA
Benzocaine Dose-Response Seen Strongest In Severe Toothache Pain – CHPA

Topics

Advertisement
UsernamePublicRestriction

Register

PS094748

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel